Amgen to advance KRAS drug combination after improved results in colon cancer

USA – Combining Amgen’s KRAS-blocking drug Lumakras with an older targeted therapy appeared to result in a higher rate of treatment responses among patients with advanced colon cancer than was previously reported for Lumakras alone, spurring the biotech company to launch a larger Phase 3 trial of the drug pairing. The new results, announced by Amgen ahead of a presentation at the European Society of Medical Oncology’s virtual annual meeting, are from an early study that tested Lumakras together with Vectibix, an approved colon cancer drug also developed by Amgen.…

Read More

FDA approves targeted therapy for KRAS lung cancer mutation

U.S – The Food and Drug Administration has approved a targeted therapy drug by AMGEN INC for non-small cell lung cancer with a specific mutation in a gene known as KRAS. The drug, sotorasib, which will be sold under the brand name Lumakras, shrank tumours with the KRAS mutation in around 36 percent of patients in clinical trials. This medication is designed to target a gene mutation known as KRAS G12C that occurs in about 13 percent of non-small cell lung cancers, or NSCLC, the most common type of lung…

Read More